Skip to main content Skip to section navigation Skip to footer
180 Life Sciences Corp.
  • Home
  • Home
  • About Us
  • Programs
    • Anti-TNF
    • Synthetic CBD Analogs (SCAs)
    • a7nAChR Program
  • Pipeline
  • Leadership
  • Investors
  • Contact Us
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 17, 2020 8:00am EST

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

Nov 10, 2020 11:45am EST

180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV

Oct 06, 2020 2:57pm EDT

UPDATE: 180 Life Sciences Corp. Expands Intellectual Property Portfolio

Oct 06, 2020 2:25pm EDT

180 Life Sciences Corp. Expands Intellectual Property Portfolio

Oct 05, 2020 1:00pm EDT

180 Life Science Corp. Announces New Board of Directors Appointments

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© Copyright 2012 - 2025 | 180 Life Sciences Corp. | All Rights Reserved.
  • Visit us on Twitter Twitter
  • Visit us on Linkedin Linkedin